🚀 Thrilled to share a new work with my friends Vincenzo Venerito & Dr. Fabian Proft ! 🎉 We explore the evolution of #axSpA treatment, from early intervention with biologics and synthetic drugs to personalized strategies for optimal outcomes. 🩺🔬 tandfonline.com/doi/full/10.10…

🌟 Exciting new recommendations for a standardized MRI protocol to evaluate SIJ´s! The ASAS SPARTAN collab introduces a 4-sequence standard to improve sacroiliitis diagnosis. 🔍✨ Check it out 📚🔗: ard.bmj.com/content/early/… #MedicalImaging #MRI #axSpA

🚨Review on RA Prevention by Cope et al.: Can we stop RA before it starts? 🔬🚫 ✅ Rituximab & Abatacept can delay RA onset ❌ Steroids & Statins showed no impact 🎯 Next-gen trials focus on precision-based prevention to stop RA in its tracks! 🔗 ard.bmj.com/content/early/…

💡 Exciting new research showcases the potential of CD19-CAR T-cell therapy in autoimmune diseases! It achieves complete B-cell depletion in deep tissues 🌟🔬 , outperforming RTX Could this pave the way for long-term, drug-free remission? 💊🧬 🔗 bit.ly/4d7utou

🔬 New study reveals Protein Kinase R (PKR) is highly expressed in dermatomyositis muscle and drives IFN-β-induced muscle damage 💥🧬. Inhibiting PKR could be a promising therapeutic target to reduce muscle damage in DM patients! 💪✨ 🔗 Read more: bit.ly/4e05Kn3

Join us a week from tomorrow for an exciting recap of the latest research and key updates in psoriatic disease abstracts presented at EADV. Don’t miss the chance to dive into insightful discussions and cutting-edge advancements in the field. 🔗 Register today and be part of this

🧪Exciting Phase 1 Study Results on OA!✨ 🔹 GSK3858279, a first anti-CCL17 mAb, shows promising efficacy in treating knee pain in OA! 🔹 Results from an RCT: ✔️ Reduced pain intensity 📉 ✔️ Improved function🏋️‍♂️ ✔️ Favorable safety & tolerability 💉 ard.bmj.com/content/early/…

🔬 Exciting findings in #LupusNephritis! 🐺 🌟 Potent B cell response linked to activated granzyme K+ CD8 T cells 🔥 in the kidney with cutting-edge techniques used! 🧬🧪 👉This immune interaction could lead to innovative treatments💊 🔗 bit.ly/3A7kodH

🚨 New trial results! 💊 💉 IFX & ADA show efficacy in treating severe mucocutaneous Behçet’s syndrome🌟💥 Both anti-TNFi´s improved symptoms & QoL significantly over 6 months 🔥 ✅ 94% ADA response ✅ 64% IFX response ✅ Safe & effective! 🔗 ard.bmj.com/content/early/…

🔬Stratification by autoantibodies in SSc reveals unique molecular signatures 🧬🌟 SCL70+ pts show a pro-inflammatory, fibrotic profile 🔥, while ACA+ pts exhibit immunomodulation & tissue homeostasis 🛡️. A guide for tailored treatments strategies? 💡 🔗ard.bmj.com/content/early/…

Want to dive into experts perspectives on microbiome research in autoimmune diseases? 💩🌟 This viewpoint highlights current developments on the microbiome in RA, SLE & SpA 🔍💡 A field for microbiome-based therapies & personalized medicine? 🌱💊🎯 🔗 ard.bmj.com/content/early/…

🎥 🔬 Fascinating study using Imaging Mass Cytometry reveals 13 unique fibroblast subpopulations in SSc skin! 🧫🌟 Certain fibroblast types are linked to severe vs. mild skin fibrosis, highlighting potential targets for personalized therapies! 🎯💉 👉 ard.bmj.com/content/early/…

#ACR24 Thanks to The Lancet Rheumatology for the warm reception. It was great to see everyone Dr. Fabian Proft André Ribeiro Jeffrey Sparks MD MMSc @SattuiSEMD Mike Putman #ElizabethVolkmann

🎙️New episode out wherever you listen to your podcasts: "Managing MSK Symptoms in PsO Patients: Who Should be in the Driver Seat?" A hot debate taken from the 2024 GRAPPA Annual Meeting, this episode of Inside GRAPPA is moderated by Dr. Mio Nakamura and features Dr. Laura